Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:HRTX NASDAQ:LXEO NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.05$5.98$4.00▼$7.54$344.79M1.341.40 million shs1.17 million shsHRTXHeron Therapeutics$0.46$0.53$0.38▼$1.93$86.27M1.652.58 million shs1.16 million shsLXEOLexeo Therapeutics$4.66$4.75$3.60▼$10.99$365.90M1.42939,170 shs656,868 shsZNTLZentalis Pharmaceuticals$4.33$4.15$1.21▼$6.95$308.25M1.921.30 million shs1.21 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%-13.57%+7.75%+13.30%-7.35%HRTXHeron Therapeutics0.00%-3.17%+6.00%-61.70%-76.14%LXEOLexeo Therapeutics0.00%-0.64%-1.89%-17.23%+12.83%ZNTLZentalis Pharmaceuticals0.00%-15.26%+7.18%+1.88%+194.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.05$5.98$4.00▼$7.54$344.79M1.341.40 million shs1.17 million shsHRTXHeron Therapeutics$0.46$0.53$0.38▼$1.93$86.27M1.652.58 million shs1.16 million shsLXEOLexeo Therapeutics$4.66$4.75$3.60▼$10.99$365.90M1.42939,170 shs656,868 shsZNTLZentalis Pharmaceuticals$4.33$4.15$1.21▼$6.95$308.25M1.921.30 million shs1.21 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%-13.57%+7.75%+13.30%-7.35%HRTXHeron Therapeutics0.00%-3.17%+6.00%-61.70%-76.14%LXEOLexeo Therapeutics0.00%-0.64%-1.89%-17.23%+12.83%ZNTLZentalis Pharmaceuticals0.00%-15.26%+7.18%+1.88%+194.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.67Moderate Buy$19.00214.05% UpsideHRTXHeron Therapeutics 2.00Hold$2.50448.49% UpsideLXEOLexeo Therapeutics 2.89Moderate Buy$18.75302.36% UpsideZNTLZentalis Pharmaceuticals 2.33Hold$6.7555.89% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, LXEO, ZNTL, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026ZNTLZentalis Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.007/17/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026ZNTLZentalis Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.007/10/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/6/2026ZNTLZentalis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/29/2026ABEOAbeona Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/25/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026LXEOLexeo Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.006/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.006/2/2026HRTXHeron Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$5.82M59.24N/AN/A$2.94 per share2.06HRTXHeron Therapeutics$154.90M0.56N/AN/A$0.07 per share6.51LXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AZNTLZentalis Pharmaceuticals$67.43M4.57N/AN/A$2.99 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics$71.18M$0.976.24N/AN/AN/A-53.98%-38.52%8/13/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/14/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)ZNTLZentalis Pharmaceuticals-$137.06M-$1.73N/AN/AN/AN/A-53.61%-40.67%8/5/2026 (Estimated)Latest HRTX, LXEO, ZNTL, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2026Q2 2026HRTXHeron Therapeutics-$0.02N/AN/AN/A$42.19 millionN/A8/13/2026Q2 2026ABEOAbeona Therapeutics-$0.23N/AN/AN/A$12.24 millionN/A8/13/2026Q2 2026LXEOLexeo Therapeutics-$0.30N/AN/AN/AN/AN/A8/5/2026Q2 2026ZNTLZentalis Pharmaceuticals-$0.45N/AN/AN/AN/AN/A5/13/2026Q1 2026ABEOAbeona Therapeutics-$0.33-$0.30+$0.03-$0.30$4.57 million$8.72 million5/12/2026Q1 2026ZNTLZentalis Pharmaceuticals-$0.49-$0.50-$0.01-$0.50N/AN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.035.895.70HRTXHeron Therapeutics17.512.531.51LXEOLexeo TherapeuticsN/A14.1614.16ZNTLZentalis PharmaceuticalsN/A6.196.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%HRTXHeron Therapeutics80.01%LXEOLexeo Therapeutics60.67%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics7.10%HRTXHeron Therapeutics6.10%LXEOLexeo Therapeutics2.00%ZNTLZentalis Pharmaceuticals3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9056.99 million52.95 millionOptionableHRTXHeron Therapeutics300189.28 million177.73 millionOptionableLXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableZNTLZentalis Pharmaceuticals16071.19 million68.48 millionOptionableHRTX, LXEO, ZNTL, and ABEO HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated at Rodman & RenshawJuly 25 at 2:48 AM | americanbankingnews.comRodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)July 23, 2026 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of "Hold" from BrokeragesJuly 22, 2026 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 22, 2026 | marketbeat.comZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?July 20, 2026 | zacks.comMizuho Begins Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)July 19, 2026 | americanbankingnews.comZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026July 17, 2026 | globenewswire.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at MizuhoJuly 17, 2026 | marketbeat.comZentalis Pharmaceuticals Insider Trading Activity | NASDAQ:ZNTL | BenzingaJune 30, 2026 | benzinga.comZentalis Shareholders Back Directors, Auditors and Executive PayJune 18, 2026 | tipranks.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial StrategyMay 27, 2026 | globenewswire.comZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum ...May 21, 2026 | finance.yahoo.comZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026May 21, 2026 | globenewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressMay 12, 2026 | globenewswire.comZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerMay 5, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerApril 21, 2026 | globenewswire.comZentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetApril 20, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...April 18, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, LXEO, ZNTL, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.05 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.14 +0.09 (+1.54%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Heron Therapeutics NASDAQ:HRTX$0.46 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.46 +0.00 (+0.04%) As of 07/24/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Lexeo Therapeutics NASDAQ:LXEO$4.66 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.66 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Zentalis Pharmaceuticals NASDAQ:ZNTL$4.33 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.28 -0.05 (-1.25%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
